| Patient | Ray Charles |
|---|---|
| Date of birth | 1960-09-23 |
| Identifiers | MRN HR-ML009-SYN; SSN (made up) 000-09-5561 |
| Document date | 2026-03-03 |
| Author | Gloria Fenwick, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Blindness of both eyes since early childhood, with no light perception, in a 65-year-old man new to the practice. The cause was never diagnosed; glaucoma is often suggested. Please examine the eyes for comfort and complications and advise whether eye pressure needs checking or treatment, and what eye care he needs from here. [S]
Urgency: Routine, within four weeks, on the same day as his four-week primary care check. [S]
Questions for the consultant:
Gradual loss of sight from about age five, blind by age seven; no eye care on record in recent years. No light perception today. He reports no eye pain, redness, discharge, or headache around the eyes, and uses no eye drops. Lids and ocular surfaces look quiet on primary care examination. Independent in all daily activities using nonvisual methods and a screen reader. Opioid use disorder in sustained remission for more than thirty years without medication; naloxone nasal spray prescribed today. PHQ-9 2. No other medicines. Please send the report as an accessible electronic document; he reads with a screen reader, and he asks that each step of the examination be described before it is done [S]
Historical basis. These claims are historical evidence, not findings from a modern examination.
1 later historical claim is omitted because it describes events after the index age. See the teaching note.
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Naloxone 4 mg nasal spray, one spray in one nostril for a suspected opioid overdose; may repeat every 2 to 3 minutes in alternating nostrils | One spray (4 mg) in one nostril for suspected overdose; repeat every 2 to 3 minutes if there is no response, and call 911 | Nasal route | 2026-03-03 | active | S |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Blindness of both eyes since childhood, no light perception; cause never diagnosed | active | confirmed | H54.0X55 | S — Synthetic modern coding of the documented childhood blindness; category 5 (no light perception) is a synthetic grading of what the sources call blindness. |
| Opioid use disorder (heroin), in sustained remission for more than thirty years, without medication treatment | active | confirmed | F11.21 | S — Synthetic modern coding of the publicly admitted heroin addiction and his documented recovery; listed as an active problem because it is managed at every visit, with remission carried by the code. |
Historical biography with true dates. These events are not part of the synthetic care timeline.
| Historical date | History | Evidence |
|---|---|---|
| 1937 | Gradual loss of sight from about age five; blind by age seven; schooled at the Florida School for the Deaf and Blind | D (CLM-0003) |
| 1937 | Cause of the childhood blindness never diagnosed, by his own account; congenital juvenile glaucoma is the cause most often suggested | R (CLM-0004) |
| 1965 | Heroin addiction from the late 1940s, publicly admitted after an arrest in 1964; stopped in 1965 after rehabilitation at a California sanitarium | D (CLM-0005, CLM-0006) |
| Relative | Condition | Age at death | Evidence |
|---|---|---|---|
| mother | Died in 1945; cause not recorded in the cited source | D (CLM-0007) | |
| brother | Younger brother died by drowning in early childhood | D (CLM-0007) |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2026-03-03 | Body height | 178 | cm | S |
| 2026-03-03 | Body weight | 80 | kg | S |
| 2026-03-03 | Body mass index (BMI) [Ratio] | 25.2 | kg/m2 | S |
| 2026-03-03 | Systolic blood pressure | 128 | mm[Hg] | S |
| 2026-03-03 | Diastolic blood pressure | 78 | mm[Hg] | S |
| 2026-03-03 | Heart rate | 68 | /min | S |
| 2026-03-03 | Respiratory rate | 14 | /min | S |
| 2026-03-03 | Body temperature | 36.7 | Cel | S |
| 2026-03-03 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2026-03-03 | Hemoglobin [Mass/volume] in Blood | 14.2 | g/dL | 13.2-16.6 g/dL | Normal | S |
| 2026-03-03 | Sodium [Moles/volume] in Serum or Plasma | 139 | mmol/L | 135-145 mmol/L | Normal | S |
| 2026-03-03 | Potassium [Moles/volume] in Serum or Plasma | 4.2 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 2026-03-03 | Creatinine [Mass/volume] in Serum or Plasma | 0.98 | mg/dL | 0.74-1.35 mg/dL | Normal | S |
| 2026-03-03 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 84 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Normal | S |
| 2026-03-03 | Glucose [Mass/volume] in Serum or Plasma | 94 | mg/dL | 70-99 mg/dL | Normal | S |
| 2026-03-03 | Calcium [Mass/volume] in Serum or Plasma | 9.4 | mg/dL | 8.6-10.3 mg/dL | Normal | S |
| 2026-03-03 | Cholesterol [Mass/volume] in Serum or Plasma | 186 | mg/dL | <=200 mg/dL | Normal | S |
| 2026-03-03 | Cholesterol in HDL [Mass/volume] in Serum or Plasma | 54 | mg/dL | >=40 mg/dL | Normal | S |
| 2026-03-03 | Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation | 110 | mg/dL | <=129 mg/dL | Normal | S |
| 2026-03-03 | Triglyceride [Mass/volume] in Serum or Plasma | 110 | mg/dL | <=149 mg/dL | Normal | S |
| 2026-03-03 | Hemoglobin A1c/Hemoglobin.total in Blood | 5.5 | % | <=5.6% | Normal | S |
| 2026-03-03 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 2 | {score} | S | ||
| 2026-03-03 | Total score [AUDIT-C] | 2 | {score} | S | ||
| 2026-03-03 | Total score [DAST-10] | 0 | {score} | S |